These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15304388)

  • 1. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
    Corbin AS; Griswold IJ; La Rosée P; Yee KW; Heinrich MC; Reimer CL; Druker BJ; Deininger MW
    Blood; 2004 Dec; 104(12):3754-7. PubMed ID: 15304388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
    Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
    Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N; Hirota S
    Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
    Griswold IJ; Shen LJ; La Rosée P; Demehri S; Heinrich MC; Braziel RM; McGreevey L; Haley AD; Giese N; Druker BJ; Deininger MW
    Blood; 2004 Nov; 104(9):2912-8. PubMed ID: 15242881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
    Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
    Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
    Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
    J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
    Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
    Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
    Clark JJ; Cools J; Curley DP; Yu JC; Lokker NA; Giese NA; Gilliland DG
    Blood; 2004 Nov; 104(9):2867-72. PubMed ID: 15256420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
    Ma Y; Zeng S; Metcalfe DD; Akin C; Dimitrijevic S; Butterfield JH; McMahon G; Longley BJ
    Blood; 2002 Mar; 99(5):1741-4. PubMed ID: 11861291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
    Corbin AS; Demehri S; Griswold IJ; Wang Y; Metcalf CA; Sundaramoorthi R; Shakespeare WC; Snodgrass J; Wardwell S; Dalgarno D; Iuliucci J; Sawyer TK; Heinrich MC; Druker BJ; Deininger MW
    Blood; 2005 Jul; 106(1):227-34. PubMed ID: 15746079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
    Faderl S; Pal A; Bornmann W; Albitar M; Maxwell D; Van Q; Peng Z; Harris D; Liu Z; Hazan-Halevy I; Kantarjian HM; Estrov Z
    Cancer Res; 2009 May; 69(9):3910-7. PubMed ID: 19383925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
    Corbacioglu S; Kilic M; Westhoff MA; Reinhardt D; Fulda S; Debatin KM
    Blood; 2006 Nov; 108(10):3504-13. PubMed ID: 16840725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.